Jan 12, 2021
Dr. Lance Okeke is an infectious disease specialist and COVID-19 site principal investigator for the ACTIV-2 clinical trial at Duke University. We talk about the historical mistrust of clinical trials among Black communities, the clinical trial and who’s eligible to participate in the study.
In April, 2020 the National Institutes of Health (NIH) announced Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding development of the most promising treatments and vaccines. You’ve no doubt heard about the vaccine to help prevent covid 19 infections, but there is also a need to find effective treatments for people with Covid 19. In this series you'll hear first hand from an infectious disease specialist, a community advisor and a clinical trial participant about the need to diversify the study to help save lives.